on MEDINCELL (EPA:MEDCL)
Medincell's Rising Revenue and Upcoming Submissions
On July 30, 2025, Medincell announced an upward revision of its 2025 revenue outlook for UZEDY®, a subcutaneous risperidone treatment for schizophrenia. The expected revenue is now projected between $190 million and $200 million, up from the previous forecast of approximately $160 million. UZEDY® has been commercialized in the U.S. since May 2023, with 2024 sales recorded at $117 million. The first half of 2025 saw sales increase to $93 million, a 2.3x rise from the same period in 2024.
Additionally, Medincell's Olanzapine Long-Acting Injectable is on track for a New Drug Application (NDA) submission in Q4 2025. The completion of its Phase 3 trial in January 2025 showed positive efficacy results. Upon approval, Medincell is poised to receive significant royalties and milestone payments.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MEDINCELL news